Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon (BME: ORY) strengthens iadademstat patent portfolio
Published by Arron Aatkar, PhD

Oryzon Genomics has announced the receipt of a ‘Decision to grant’ from the Japanese Patent Office for its patent application ‘Combinations of iadademstat for cancer therapy’. This covers the use of iadademstat in combination with immune checkpoint inhibitors such as atezolizumab and durvalumab in small cell lung cancer, an indication that Oryzon is pursuing in active clinical trials. Once granted, this patent will remain in place until at least 2040, excluding any other potential patent term extensions. Management noted that it has secured corresponding patents in Europe, Japan, Australia and Russia, with additional applications pending in other key regions.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.